What to ask your clinician before any weight-loss intervention.

Prepared September 15, 2026 · Publisher review required · No clinician review claimed

A pre-appointment checklist of questions to bring to a licensed clinician when considering any weight-loss, hormone, or metabolic intervention — including investigational ones. This page is a question list, not a recommendation.

Before the appointment

What are you hoping to change?

A clear, written goal helps your clinician understand what outcome you are seeking and why. “Lose weight” is broad; “reach a stable weight that improves my blood pressure and lets me keep up with my kids” is specific. Specific goals are easier to evaluate honestly later.

What is your medical history relevant to this?

Bring a list of current conditions (especially thyroid, pancreatic, gallbladder, kidney, liver, mental health, eating history), prior surgeries, and current medications including supplements. Be specific about prior weight-loss attempts — what was tried, for how long, and what happened.

What is your family history?

Family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, gallbladder disease, severe gastroparesis, or eating disorders changes the risk profile of multiple weight-loss drug classes.

During the appointment

For any proposed treatment, ask:

• What is the FDA status of this drug? Approved, designated (fast track, breakthrough, priority review), investigational, or compounded? Ask for the FDA approval letter or IND reference if applicable.
• What is the indication? An FDA approval is for a specific indication. Use outside the approved indication is off-label and changes the evidence base the clinician can rely on.
• What does the label say about contraindications and warnings? Read it yourself on DailyMed or the FDA label PDF.
• What clinical trials support this for someone like me? Ask specifically about age, sex, BMI, comorbidities, and prior treatment history. “Works” in a 45-year-old woman without diabetes is different from “works” in a 60-year-old man with cardiovascular disease.
• What are the common and serious side effects, and how will we monitor? “Watch for X” is not a plan; “we will run Y labs at Z intervals” is.
• How long should I expect to take this, and what is the exit plan? Some interventions are intended for short-term use; others are intended indefinitely. Both are legitimate, but you should know which.
• What happens if I stop? Weight regain after stopping a weight-loss drug is common. Ask how that would be managed.
• What does this cost, and what is the cash price if insurance does not cover it? List price, your copay with your plan, and the cash-pay option if available.
• Are there interactions with my other medications or supplements? Bring the list.

If the intervention is investigational

Additional questions for clinical-trial or expanded-access participation:

• Is this a registered clinical trial on ClinicalTrials.gov, and what is the NCT identifier?
• Is the trial recruiting in my area?
• What is the randomization (placebo-controlled, active comparator, open-label)?
• What is the primary endpoint, and what would a positive result mean for me?
• Will I be told which arm I am in, and when?
• What are the sponsor’s plans after the trial ends — will the drug be available to me, and at what cost?
• Is this expanded access (single-patient IND, intermediate-size population, treatment IND), and what does the FDA say about that pathway?

ClinicalTrials.gov is the official registry of federally and privately supported clinical trials. Listing on ClinicalTrials.gov does not mean the trial is currently recruiting or that the site has been verified. S06: Finding a Clinical Trial — NIH S07: Search retatrutide trial records — ClinicalTrials.gov

Red flags to notice

• No questions asked. A clinician who prescribes without asking about your history, prior attempts, medications, or family history is not following standard practice.
• No monitoring plan. Any drug with meaningful side effects requires baseline and follow-up labs, vitals, or symptom checks. “Take this and come back in a year” is unusual.
• Cash-only, no insurance, no records. Standard practice includes a medical record you can request, an itemized receipt, and the ability to submit to insurance if applicable.
• Claims that contradict the FDA label or trial evidence. If the clinician claims a drug “cures,” “is safer than,” or “is approved for” something not on the label, ask for the source.
• Pressure to start before you have read the consent. A signed informed consent is a precondition for trial participation, not an afterthought.

After the appointment

Take notes and keep your own record.

Record what was discussed, what was prescribed (drug, dose, route, frequency, duration), what monitoring was planned, and what follow-up was scheduled. Federal law gives you the right to request copies of your medical record.

Re-evaluate on a schedule.

Weight, blood pressure, and lab values are not the only outcomes that matter. Sleep, mood, energy, food relationship, and quality of life are also measurable. Define your re-evaluation points in advance.

Tell your clinician the truth about adherence.

If you stopped a medication because of side effects or cost, say so. Non-disclosure makes it harder to find a regimen that actually works for you.